Abstract Details

Title Cystatin C as a Marker of Degeneration in Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 241

Objective

Background BACKGROUND: Goal of the study: Ask the question, wheather cystatin C level in the CSF could be a marker of neurodegeneration in multiple sclerosis.

Design/Methods DESIGN/METHODS: A total 258 patients was studied, 120 patients with MS and 138 controls with non-inflammatory diseases of the CNS (e.g. stroke, headache, low.back pain). MS patients group included 29 patients with CIS, 77 patients with RRMS, 6 patients with PP and 8 patients in secondary progression. Serum and CSF samples was testing using ELISA method. In all MS patients was neurological examination and EDSS performed. Acquired data was subject to statistical analysis, the signifikance level was 0.05 for all tests.

Results RESULTS: Kruskal-Wallis test suggest statistical signifiant diferences in medians and means of cystatin C levels in both compartments in evaluated groups (P=0.004). Consequently Mann-Whitney test noted significantly lower cystatin C concentration in RR patients in comparisson with controls (P=0.015). Cystatin index (cystatin C in CSF/ cystatin C in serum) evinced similar results. Correlation between cystatin C and EDSS values using Spearmans rho did not confirm statistic dependence of these parameters (CIS: P=0.254; RR: P=0.774; SP: P=0.558; PP: P=0.624).

Conclusions CONCLUSIONS: Cystatin C concentration decrease in RR form of MS could give evidence for high disease activity in this stage of the disease with high myelin damage and neurodegeneration.

Authors/Disclosures
Hana Prikrylova Vranova (Teva Pharmaceuticals CR) PRESENTER	No disclosure on file
	No disclosure on file
Jan Mares, MD	Dr. Mares has nothing to disclose.
Ugur Uygunoglu (Cerrahpasa)	Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
Petr Hlustik, MD, PhD (Palacký University Olomouc)	The institution of Prof. Hlustik has received research support from Czech Health Research Council (AZV CR).
	No disclosure on file
Petr Kanovsky, PhD	Dr. Kanovsky has nothing to disclose.
Orrin Devinsky, MD, FAAN (NYU Epilepsy Center)	Dr. Devinsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for California Cannabis Enterprises. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Privateer Holdings. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Receptor Holdings. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rettco. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Silver Spike. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tevard. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Tilray. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Tevard Biosciences. Dr. Devinsky has stock in Engage. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in California Cannabis Enterprises. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in Silver Spike. Dr. Devinsky has stock in Docklight Brands. Dr. Devinsky has stock in Egg Rock/Papa Barkley. Dr. Devinsky has stock in Leafly. Dr. Devinsky has stock in Left Coast Ventures. Dr. Devinsky has stock in Privateer Holdings. Dr. Devinsky has stock in Receptor Holdings. Dr. Devinsky has stock in Qstate. The institution of Dr. Devinsky has received research support from GW Pharma. The institution of Dr. Devinsky has received research support from Zogenix. The institution of Dr. Devinsky has received research support from PTC Pharma. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from DOD. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from Epilepsy Foundation. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NSF. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��